
|Videos|November 17, 2018
Rationale for the Strong Response to Immunotherapy in Melanoma
Author(s)Hussein A. Tawbi, MD, PhD
Hussein A. Tawbi, MD, PhD, discusses why melanoma responds so well to immunotherapy.
Advertisement
Hussein A. Tawbi, MD, PhD, director of Melanoma Clinical Research and Early Drug Development in the Department of Melanoma Medical Oncology at The University of Texas MD Anderson Cancer Center, discusses why melanoma responds so well to immunotherapy.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Priority Review to Dato-DXd First-Line Metastatic TNBC
2
Dr Shubham Pant Highlights Progress and Promise in Pancreatic Cancer Treatment
3
FDA Accepts NDA of Zanzalintinib Combo for Pretreated Metastatic CRC
4
New Phase 2 Study of Tri-Modal Immunotherapy for Indolent B-Cell Lymphoma Launches
5




















